US FDA's 510(k) clearance of TransEnterix Inc.'s Senhance System could pave the way for big changes in laparoscopic surgery by increasing the number of such surgeries done with robotically-assisted surgical devices (RASD). But the new system is unlikely to pose a direct threat to Intuitive Surgical Inc.'s daVinci product line, analysts suggest.
FDA cleared the Senhance System Oct. 13 for minimally invasive surgeries including gynecological and colorectal procedures.





